PARTNER 3: TAVR benefit persists at 1 year in low-risk patients with severe AS
14 Oct 2019
byElaine Soliven
In low-risk patients with severe aortic stenosis (AS), those treated with transcatheter aortic valve replacement (TAVR) had a significantly better disease-specific health status at 1 year compared with those who received surgical aortic valve replacement (SAVR), according to the PARTNER 3* trial presented at TCT 2019.